Ligandrol (LGD-4033), a novel nonsteroidal oral, selective androgen receptor modulator, binds androgen receptor with high affinity and selectivity.

Ligandrol (LGD-4033) has demonstrated anabolic activity in the muscle, anti-resorptive and anabolic activity in bone, and robust selectivity for muscle versus prostate In animal models. Ligandrol is well tolerated, has a long elimination half-life and dose-proportional accumulation upon multiple dosing. Ligandrol is safe, has favorable pharmacokinetic profile, and increases lean body mass even during this short period without change in prostate-specific antigen.